Skip to main content
Premium Trial:

Request an Annual Quote

Burrill, Infinity Partner to Explore Life Science Opps in China

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life science venture capital and private equity firm Burrill & Co. and the Infinity Group today announced a joint venture to pursue life science investment opportunities in China.

Under the agreement, the two companies will co-invest into life science opportunities in China in US dollars and in renminbi, the currency of mainland China. Burrill, headquartered in San Francisco, will establish headquarters in Hong Kong for its China operations. Infinity already has a presence in Hong Kong, the two firms said in a joint statement.

Burrill will also use Infinity's 10 offices in China and its international offices in the US, Europe and Asia. In return, the partnership allows Infinity to strengthen its presence in the US, as part of its strategy to increase its presence as a global life science fund "bringing innovative technologies from Israel, the US, and Europe to China," the two companies said.

Based in Israel, Infinity describes itself on its website as "the world's leading cross-border Chinese focused management group" and manages more than $1 billion RMB and $700 million through 10 funds, including eight in China.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.